Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value (DNTH)

Historical Holders from Q3 2023 to Q3 2025

Symbol
DNTH on Nasdaq
Type / Class
Equity / Common Stock, $0.001 par value
Shares outstanding
43,666,020
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
46,828,772
Holdings value
$1,842,663,442
% of all portfolios
0.01%
Number of holders
140
Number of buys
94
Number of sells
-46
Average buys %
+0.01%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value (DNTH)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 15% +7.1% $234,944,605 +$58,553,941 5,970,638 +33% FMR LLC 30 Sep 2025
RA CAPITAL MANAGEMENT, L.P. 9.5% +6.7% $152,155,944 +$39,350,000 3,866,733 +35% RA Capital Management, L.P. 30 Sep 2025
WELLINGTON MANAGEMENT GROUP LLP 6.5% $101,431,000 2,577,662 Wellington Management Group LLP 30 Sep 2025
Octagon Capital Advisors LP 6.1% -14% $95,095,846 +$12,060,775 2,416,667 +15% Octagon Capital Advisors LP 30 Sep 2025
Fairmount Funds Management LLC 4.9% -50% $72,191,285 -$64,524,950 2,139,635 -47% Fairmount Funds Management LLC 21 Nov 2025
Point72 Asset Management, L.P. 5.3% +16% $44,225,769 +$14,080,318 2,121,140 +47% Point72 Asset Management, L.P. 11 Sep 2025
Avidity Partners Management LP 4.9% -50% $70,995,168 -$43,010,234 2,104,184 -38% Avidity Partners Management LP 17 Nov 2025
BlackRock, Inc. 5% $34,803,328 1,600,153 BlackRock, Inc. 31 Mar 2025
TCG Crossover GP II, LLC 4.7% $32,660,322 1,501,624 TCG Crossover GP II, LLC 31 Mar 2025
BCLS Fund III Investments, LP 3.1% -55% $51,780,350 -$45,896,187 1,315,892 -47% BCLS Fund III Investments, LP 30 Sep 2025
Vestal Point Capital, LP 3% -70% $46,433,000 -$79,487,000 1,180,000 -63% Vestal Point Capital, LP 30 Sep 2025
Venrock Healthcare Capital Partners III, L.P. 3.1% $20,060,000 1,000,000 Venrock Healthcare Capital Partners III, L.P. 30 Jun 2025

Institutional Holders of Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value (DNTH)

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 46,828,772 $1,842,663,442 +$358,133,968 $39.35 140
2025 Q2 39,106,709 $728,558,630 +$24,440,177 $18.63 101
2025 Q1 37,715,319 $685,461,303 +$43,246,773 $18.14 97
2024 Q4 35,126,689 $765,706,199 +$63,092,353 $21.8 94
2024 Q3 31,364,805 $858,714,506 +$44,837,092 $27.38 90
2024 Q2 29,702,499 $768,778,734 +$87,583,327 $25.88 74
2024 Q1 26,075,021 $782,250,559 +$479,966,613 $30 75
2023 Q4 10,291,119 $106,507,945 +$518,588 $10.4 38
2023 Q3 10,072,640 $136,328,208 +$136,328,208 $13.67 30